AR and prostate carcinoma: By examining prostate cancer biopsies from patients treated with the AR pathway inhibitor (ARPI) enzalutamide, we previously found that a subset of tumors underwent lineage plasticity from AR-driven prostate cancer (ARPC) to DNPC (6).